Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

14.56
+0.78505.70%
Post-market: 14.700.1400+0.96%19:30 EDT
Volume:1.10M
Turnover:15.89M
Market Cap:1.24B
PE:-8.34
High:14.84
Open:14.06
Low:14.00
Close:13.78
52wk High:25.77
52wk Low:4.54
Shares:85.31M
Float Shares:54.48M
Volume Ratio:0.89
T/O Rate:2.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7450
EPS(LYR):-0.4650
ROE:-42.66%
ROA:-21.63%
PB:2.55
PE(LYR):-31.31

Loading ...

Monte Rosa posts corporate deck spotlighting molecular glue degrader pipeline for immunology, inflammation and cancer targets

Reuters
·
Jun 01

Monte Rosa COO Jennifer Champoux disposes of 2,175 shares for $43,500

Reuters
·
May 29

Monte Rosa COO Jennifer Champoux sells 2,176 common shares worth $41,344

Reuters
·
May 27

Insider Shake-Up at Monte Rosa Therapeutics Sparks Investor Buzz

TIPRANKS
·
May 23

Monte Rosa director Anthony Manning disposes 10,000 shares worth $180,100

Reuters
·
May 23

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 20

Monte Rosa Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
May 12

Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
May 08

Monte Rosa Therapeutics reports Q1 revenue $4.21M, consensus $11.39M

TIPRANKS
·
May 08

Monte Rosa Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Monte Rosa Therapeutics Q1 collaboration revenue drops 95%

Reuters
·
May 07

Monte Rosa publishes investor presentation on molecular glue degrader pipeline and Phase 2 plans

Reuters
·
May 07

Monte Rosa Q1 FY26 net loss widens to $44.5 million; revenue falls to $4.2 million

Reuters
·
May 07

BRIEF-Monte Rosa Therapeutics Q1 Net Income USD -44.503 Million

Reuters
·
May 07

Monte Rosa Therapeutics Q1 Operating Expenses USD 54.244 Million

THOMSON REUTERS
·
May 07

Monte Rosa Therapeutics Q1 Operating Income USD -50.034 Million

THOMSON REUTERS
·
May 07

Press Release: Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Dow Jones
·
May 07

Monte Rosa CEO Markus Warmuth sells 5,467 shares for $103,443.57

Reuters
·
May 06

Monte Rosa grants inducement awards: options for 38,925 shares at $18.8 exercise price

Reuters
·
May 06

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 06